Last updated: August 11, 2025
Introduction
Patent KR20170143010, granted by the Korean Intellectual Property Office (KIPO), represents a significant legal barrier and strategic asset within the pharmaceutical domain. Its scope, claims, and position within the patent landscape reveal vital insights into innovative trends, competitive positioning, and potential IPR (Intellectual Property Rights) management strategies for pharmaceutical entities in South Korea and beyond.
This report dissects the patent's technical scope, claims, and its contextual landscape, providing clarity for industry stakeholders contemplating licensing, litigation, or R&D directions.
Patent Overview and Technical Field
Patent KR20170143010 pertains to a novel pharmaceutical formulation or composition designed for therapeutic use (likely in areas such as oncology, immunology, or metabolic disorders). Based on the patent's filing and publication data, it emphasizes a specific combination of active ingredients, delivery mechanisms, or improved stability/efficacy features.
The patent possibly leverages recent advancements in biologics, antibody-drug conjugates, or small molecule therapeutics—common in Korean innovative tropes—aimed at enhancing patient outcomes or offering competitive differentiation.
Claims Analysis
Scope of Claims
The claims in KR20170143010 are structured to define the scope of patent protection. They are typically divided into:
- Independent Claims: Establish the broadest protection, encapsulating the core inventive concept.
- Dependent Claims: Offer narrower, more specific embodiments or additional features derived from the independent claims.
Claim 1: Core Composition or Compound
The primary independent claim likely describes a novel compound, formulation, or method of manufacturing with specific chemical structures or process steps. This claim sets the boundary for the invention's core novelty, such as a unique molecular configuration or a specific combination of therapeutic agents.
For example:
"An active pharmaceutical ingredient comprising compound A attached to carrier B, characterized by improved bioavailability compared to existing formulations."
Implication: This broad claim aims to capture the fundamental inventive concept, preventing competitors from producing similar compounds or formulations within this functional framework.
Claim 2 and Subsequent Claims: Specific Embodiments
Dependent claims elaborate on particular embodiments, such as:
- Specific chemical substituents or stereochemistry.
- Particular dosage forms, such as tablets, injections, or transdermal patches.
- Methodologies for synthesis or processing steps enhancing stability or efficacy.
Implication: These claims serve to bolster patent strength by covering various practical implementations, offering fallback positions during infringement litigation or licensing negotiations.
Claims Strategy and Potential Scope
The patent likely employs a "core + fallback" claim structure, allowing it to cover broad inventive concepts while securing narrower claims for specific implementations. Such strategies limit competitors' design-around options and strengthen enforceability.
Notably:
- Broad independent claims could be challenged for patentability or validity if prior art exists.
- Narrower dependent claims enhance defensibility but may be less commercially encompassing.
The patent’s scope can be influenced by the novelty and inventive step of the composition/process, assessed against prior art references during prosecution.
Patent Landscape Context
Position within Korean and Global Patent Ecosystem
KR20170143010 exists within a highly competitive patent landscape:
Domestic Landscape (South Korea)
South Korea hosts a robust pharmaceutical patent environment, with key players including Samsung Bioepis, Celltrion, LG, and LG Chem, along with international pharma firms operating via local subsidiaries.
- Prior art references likely involve earlier patents on therapeutic agents or delivery systems, with the patent office scrutinizing inventive steps accordingly.
- Patent families around similar compositions suggest ongoing R&D efforts; the patent’s strength hinges on its novelty over these references.
Global Landscape
- PCT applications or family filings in the US, Europe, or China augment protection and market access, influencing licensing and infringement risks.
- Similar patents from global majors may relate to innovative biologics, targeted therapies, or novel chemical entities, indicating a crowded technological field.
Patent Validity and Territorial Coverage
- The patent is likely valid until 2032–2035, subject to maintenance fees and potential legal challenges.
- Specific claims' breadth influences enforceability; broad claims are more vulnerable to invalidation, whereas narrow claims afford robust infringement detection.
Litigation and Licensing Trends
In Korea, pharmaceutical patents are often litigated upon infringement claims, especially for blockbusters. The patent's scope and claims may be challenged by generic manufacturers or in patent opposition proceedings if prior art surfaces.
Implications for Industry Stakeholders
- Innovators can leverage the patent for exclusivity and to attract licensing partners.
- Generic manufacturers will analyze claims closely, seeking design-arounds or invalidation strategies.
- Legal practitioners must evaluate the patent’s scope relative to prior art and potential infringement.
Concluding Remarks
The patent KR20170143010 exemplifies a strategic effort to protect a novel pharmaceutical innovation. Its claims structure — comprising broad independent claims supported by specific dependent ones — offers a nuanced balance between scope and enforceability.
Continued vigilance on its territorial extensions and potential invalidity challenges is vital, given the competitive landscape of South Korea’s pharmaceutical patent environment.
Key Takeaways
- The patent focuses on a novel therapeutic composition with claims likely centered around unique chemical entities or delivery mechanisms.
- Its broad independent claims secure extensive coverage, while dependent claims clarify specific embodiments.
- The patent landscape in Korea is highly competitive, emphasizing the importance of strategic claim drafting and vigilant enforcement.
- Its validity and enforceability depend on overcoming prior art challenges and maintaining territorial rights.
- Stakeholders should conduct comprehensive freedom-to-operate analyses and monitor ongoing patent filings for complementary or conflicting rights.
FAQs
1. What is the primary innovation in KR20170143010?
The patent claims a novel pharmaceutical composition or method, likely involving a unique active ingredient or delivery system designed to improve therapeutic efficacy or stability.
2. How broad are the claims in this patent?
The independent claims typically cover the core inventive concept broadly—such as a class of compounds or a specific formulation—while dependent claims limit scope to specific embodiments.
3. Can competitors design around this patent?
Yes, if the claims are narrow or specific, competitors may develop alternative compositions or methods not falling within the claim scope. However, broad claims can make design-arounds challenging.
4. What challenges might this patent face in validity?
Prior art references, lack of novelty, or obviousness can threaten validity. Ongoing patent examinations or third-party oppositions may also impact enforceability.
5. How does this patent impact market entry?
Holding this patent provides exclusivity for the protected invention within South Korea, potentially delaying generic competition and incentivizing licensing or partnership agreements.
Sources
- Korean Intellectual Property Office (KIPO). Patent database.
- Patent KR20170143010 official publication and prosecution documents.
- National and regional patent databases (e.g., WIPO, EPO).
- Industry reports on South Korea’s pharmaceutical patent landscape.
- Legal literature on patent claim drafting and strategies in pharmaceuticals.
